BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld Science
  • BioWorld Asia
  • Data Snapshots
    • Biopharma
    • Medical technology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • NME Digest
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Med-tech outlook 2026
    • Under threat: mRNA vaccine research
    • BioWorld at 35
    • Biopharma M&A scorecard
    • Bioworld 2025 review
    • BioWorld MedTech 2025 review
    • BioWorld Science 2025 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Thursday, April 23, 2026
Home » Newsletters » BioWorld Science

BioWorld Science

April 19, 2013

View Archived Issues

Royalty Pharma makes firm offer to acquire Elan

Read More

Association between rs17587 polymorphism of the PSMB9 gene and RA

Read More

Pfenex and Agila Biotech form joint venture to develop biosimilar products

Read More

Genentech presents data for novel PI3K inhibitors

Read More

Stem Cell Therapeutics licenses rights to cancer stem cell program

Read More

GPR40 agonist shows improved pharmacokinetics and selectivity

Read More

BioLineRx phase IIa study in ulcerative colitis meets primary endpoint

Read More

CanBas reports topline results from phase II trial of CBP-501 in NSCLC

Read More

Novel radioligands developed for 5-HT4 receptor imaging

Read More

PharmAthene's rBChE shown to bind to broad spectrum of nerve agents

Read More

Researchers from Ontario identify miR-605 as a novel genetic modifier in LFS

Read More

Tekmira presents preliminary phase I results for TKM-080301

Read More

Adelaide Research and Innovation presents new pneumococcal vaccines

Read More

IgenMed Pharmaceuticals presents novel fusion proteins

Read More

New bispecific antibodies divulged by Amgen

Read More

Merck & Co. discloses novel aldosterone synthase inhibitors

Read More

FDA clears SKL-15508 IND

Read More

ARMGO Pharma receives MDA support to advance novel DMD drug

Read More

Phase II trial of AeroVanc begins for MRSA lung infection in patients with cystic fibrosis

Read More

Resverlogix completes dosing in phase IIb ASSURE trial

Read More

Pluristem Therapeutics expands PLX pipeline in orthopedics and sports medicine

Read More

Targacept completes recruitment in phase IIb trial of TC-5619

Read More

Addex Therapeutics reports preclinical data for dipraglurant

Read More

Interprotein and Takeda sign new molecular design agreement

Read More

SK Biopharmaceuticals and SK Chemicals establish alliance for YKP-10811

Read More

Shin Nippon Biomedical and Besins Healthcare sign nasal drug delivery agreement

Read More

Pharmacyclics updates progression of ibrutinib trials

Read More

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for April 22, 2026.
  • Man holding raised arm with illustrated overlay of nerves

    Biohaven reports details on discovery of BHV-2100

    BioWorld Science
    Transient receptor potential melastatin 3 (TRPM3) is a calcium-permeable TRP channel that is highly expressed in somatosensory neurons, including nociceptors of...
  • Elderly woman holding illustration of brain with missing puzzle piece

    Meta-analysis: Anti-amyloid Alzheimer’s drugs not ‘clinically meaningful’

    BioWorld
    The ongoing controversy over the effectiveness of anti-amyloid drugs is about to get more heated, after a review of clinical trials showed statistically...
  • New GABA(B) receptor PAMs revealed in Addex Pharma patents

    BioWorld Science
    Addex Pharma SA has disclosed new GABA(B) receptor positive allosteric modulators (PAMs) potentially useful for the treatment of chronic cough, urinary...
  • MMP inhibitors divulged in Accure Therapeutics patent

    BioWorld Science
    Accure Therapeutics has reported new oligopeptide derivatives acting as matrix metalloproteinase-2 (MMP-2) and MMP-9 inhibitors. As such, they are described as...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Medical technology
    • Newco news
    • Opinion
    • Regulatory
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/metabolic
    • Immune
    • Infection
    • Neurology/psychiatric
    • NME Digest
    • Patents
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2026. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing